logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

Intellia Therapeutics  Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia Therapeutics ( NTLA ) announced its first Clinical Trial Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency ( MHRA ) to...

Read More

August 11, 2020

0

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today's Trading

Reata Pharmaceuticals We picked Reata Pharmaceuticals ( RETA ) for investment after confirming that the products the Company has created and is currently developing have a novel mechanism of action that enables the treatment of severe diseases that have yet...

Read More

November 27, 2020

0

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock exchange with the symbol CVAC , as of August 14, 2020. We assume you must have heard the name of this firm by now...

Read More

August 17, 2020

0

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity At the end of the trading week last Friday, November 27, 2020, the United States FDA approved Rhythm Pharmaceuticals’ ( RYTM ) product IMCIVREE™ (setmelanotide). The product is designed to treat...

Read More

December 1, 2020

0

Why Intellia Therapeutics' and Moderna's Stocks Moved South Yesterday

Intellia Therapeutics Intellia Therapeutics ( NTLA ) stock price headed south probably because some robots learned that the firm commenced an underwritten public offering of $150 million of shares of its common stock. In addition to the commenced public offering Intellia announced...

Read More

December 2, 2020

0

Moderna Encouraging News. See Also: Translate Bio and Sanofi Good News

Moderna Presented Interim Clinical Data about mRNA-1273 for COVID-19 Moderna ( MRNA ) presented new Interim Clinical Data about its mRNA Vaccine ( mRNA-1273 )  against COVID-19 at the Advisory Committee on Immunization Practices ( ACIP ) Meeting. The presentation...

Read More

August 27, 2020

0

Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals ( RYTM ) is a late-stage biopharmaceutical company with a product pipeline that reflects its focus of developing treatments for rare genetic obesity. The firm’s lead product, setmelanotide, is a melanocortin-4 receptor ( MC4R )...

Read More

August 28, 2020

0

Moderna Inc Stock is Tanking After Rallying

Moderna Inc Late August Announcements  On August 28, 2020 Moderna Inc ( MRNA ) issued a press release confirming that the Company is engaged in discussions with the Ministry of Health, Labor and Welfare of Japan ( MHLW ) to...

Read More

September 1, 2020

0

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

CRISPR, Intellia and Editas, Our Gene-Editing Sisters, are Rallying The three CRISPR gene-editing firms that we have chosen are enjoying rallies.  CRISPR Therapeutics ( CRSP ) and Intellia Therapeutics ( NTLA ) stocks’ rallying were the first to move products...

Read More

December 10, 2020

0

Acquisitions that Make Sense

Acquisitions  AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca ( AZN )  and Alexion Pharmaceuticals ( ALXN ) entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares ( ADSs )...

Read More

December 14, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 11
  • 12
  • 13
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy